Thailand Pharmaceutical Market 2025: Key Trends for Generic Medicine Importers

Thailand Pharmaceutical Market Overview

Thailand has the second-largest pharmaceutical market in Southeast Asia by value. The market is characterized by:

• →A large government healthcare sector — the Universal Health Coverage scheme covers approximately 48 million Thais
• →High generic medicine penetration in government hospital procurement (approximately 70% by volume)
• →Growing private healthcare sector with increasing demand for quality-assured imported generics
• →A pharmaceutical regulatory framework progressively aligned with international standards

For Taiwan pharmaceutical exporters, Thailand represents the most accessible and commercially established ASEAN market, with clear regulatory pathways and a mature importer network.

Market Size and Growth

Thailand's pharmaceutical market was valued at approximately USD 6 billion in 2024, with growth projected in the 5–7% per annum range through 2027. Key growth drivers include:

• →Aging population: Thailand has one of Asia's fastest-aging demographics. Chronic disease categories — cardiovascular, diabetes, CNS — are growing proportionally
• →Universal Health Coverage expansion: Government healthcare spending continues to increase
• →Private hospital expansion: Bangkok and major provincial cities are seeing continued private hospital development
• →Regulatory modernization: Thai FDA's ongoing alignment with PIC/S GMP and ACTD standards is increasing the proportion of regulated quality imports

Therapeutic Categories with Strong Growth Potential

Cardiovascular: Thailand's growing elderly population drives strong demand for antihypertensives, statins, anticoagulants, and antiplatelet agents. Cardiovascular generics are among the highest-volume categories in government hospital procurement.

Diabetes and Metabolic: Diabetes prevalence in Thailand is rising — estimated at over 4 million diagnosed cases. Oral antidiabetic agents continue to see volume growth.

Anti-infectives: Antibiotics and antivirals remain high-volume categories in government hospital formularies.

CNS and Neurological: Antiepileptic drugs, antidepressants, and dementia-related medications are growing with Thailand's aging demographic profile.

Oncology: Government hospital oncology programs are expanding. Generic oncology agents represent a growing opportunity.

Import Sources and Competitive Landscape

• →India: Largest supplier by volume, price-competitive but significant quality variation
• →Europe: Premium products in specialty and branded generic segments
• →Taiwan: Increasingly recognized for quality-assured PIC/S GMP generics with documentation strength — positioned above India in the quality tier
• →China: Growing presence but facing ongoing GMP credibility challenges in Thailand government hospital procurement

2025 Trends to Watch

• →Stricter GMP enforcement by Thai FDA: New enforcement actions against manufacturers with GMP deficiencies. PIC/S certified manufacturers benefit.
• →Post-pandemic supply chain diversification: Thai hospital procurement teams are increasingly interested in supply diversification — creating opportunities for Taiwan manufacturers as alternative quality suppliers.
• →Digital health integration: Thai hospitals are investing in pharmacy management systems, creating demand for accurate product documentation.

Summary

Thailand's pharmaceutical market in 2025 offers clear and growing opportunities for Taiwan generic pharmaceutical exporters who combine quality GMP manufacturing with complete registration documentation and reliable supply capability.